Ocular Therapeutix Q2 EPS $(0.26) Beats $(0.29) Estimate, Sales $15.19M Beat $14.64M Estimate
Portfolio Pulse from bharat@benzinga.com
Ocular Therapeutix reported Q2 earnings per share (EPS) of $(0.26), beating the analyst consensus estimate of $(0.29) by 10.34%. The company also reported quarterly sales of $15.19 million, surpassing the analyst consensus estimate of $14.64 million by 3.73%. This represents a 23.81% increase over sales from the same period last year.
August 07, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's Q2 earnings and sales beat analyst estimates, which could positively impact the company's stock.
Ocular Therapeutix's Q2 earnings and sales exceeded analyst estimates, which is typically a positive signal for investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100